Brief: Paion Announces That NMPA Accepts Submission Of New Drug Application For Remimazolam By Chinese Licensee Yichang Humanwell
16/11/2018 09:49
Nov 16 (Reuters) - PAION AG PA8G.DE :
* ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG
APPLICATION
FOR REMIMAZOLAM BY CHINESE LICENSEE YICHANG HUMANWELL
* NDA SUBMISSION TRIGGERS MILESTONE PAYMENT OF EUR 0.5
MILLION TO
PAION
Source text for Eikon: ID:nEQb1ycrja
Further company coverage: PA8G.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022